Quantcast
Last updated on April 16, 2014 at 13:13 EDT

Latest Dasatinib Stories

2014-01-09 08:28:38

LONDON, Jan. 9, 2014 /PRNewswire/ -- The Avillion Group (Avillion), a co-developer of late-stage clinical assets, announced today that it has entered into an exclusive collaborative development agreement with Pfizer Inc. to conduct a global Phase 3 clinical trial of Pfizer's BOSULIF(®) (bosutinib). The trial, which will be conducted across multiple sites in the United States, Asia and Europe, will evaluate BOSULIF, administered at a starting dose level of 400 mg daily, as a...

2013-06-26 08:28:20

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, June 26, 2013 /PRNewswire/ -- Today, Wall Street Reports announced new research reports highlighting Bristol-Myers Squibb Company (NYSE: BMY), Celgene Corporation (NASDAQ: CELG), Aetna Inc. (NYSE: AET), Theravance Inc. (NASDAQ: THRX) and MannKind Corporation (NASDAQ: MNKD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst...

2013-03-21 14:58:25

Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides. The therapy may not be effective for all patients, but those with trisomy 8 chromosomal disorder have higher rates of stable disease and respond better to treatment with dasatinib,...

2012-11-29 14:56:43

HOUSTON — A previously invincible mutation in chronic myeloid leukemia (CML) has been thwarted by an investigational drug in a phase I clinical trial reported in the current edition of The New England Journal of Medicine. All 12 patients in the trial with chronic phase CML and the T315I mutation had a complete hematologic response (absence of CML cells in the blood) after treatment with ponatinib. Eleven had a major reduction in CML cells in the bone marrow and nine achieved a...

2012-08-13 22:03:30

Discovery of the genetic basis of a high-risk subtype of leukemia shows some patients might benefit from existing targeted therapies, advancing the goal of curing all children with the most common childhood cancer Scientists have identified new genetic alterations underlying a high-risk subtype of the most common childhood cancer that could be effectively targeted with existing leukemia therapies. The study focused on a subtype of acute lymphoblastic leukemia (ALL) known as Philadelphia...

2012-08-13 06:25:12

Discovery of the genetic basis of a high-risk subtype of leukemia shows some patients might benefit from existing targeted therapies, advancing the goal of curing all children with the most common childhood cancer MEMPHIS, Tenn., Aug. 13, 2012 /PRNewswire-USNewswire/ -- Scientists have identified new genetic alterations underlying a high-risk subtype of the most common childhood cancer that could be effectively targeted with existing leukemia therapies. The study focused on a subtype of...

2012-06-17 22:22:09

AMSTERDAM and CAMBRIDGE, Massachusetts, June 18, 2012 /PRNewswire/ -- ~ Robust anti-leukemic activity in CML patients who have become resistant or intolerant to available tyrosine kinase inhibitors ~ 54% major cytogenetic response and 30% major molecular response reported in heavily pre-treated chronic-phase CML patients ~ Data supports ARIAD filing for EMA approval of ponatinib in Europe ARIAD...

2012-06-15 10:23:01

PARIS, June 15, 2012 /PRNewswire/ -- Results Presented at 17th Congress of the European Hematology Association Bristol-Myers Squibb Company (NYSE:BMY) and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL(R) (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia (CP-CML) adult patients resistant or intolerant to Glivec(R)...

2012-06-14 22:20:42

AMSTERDAM, June 15, 2012 /PRNewswire/ -- At the 17th Congress of the European Hematology Association in Amsterdam Professor Max Topp of the University of Wuerzberg in Germany presents the impressive results with a bispecific antibody for Acute Lymphoblastic Leukemia patients. The Phase 2 dose-ranging study MT103-206 evaluated the efficacy, safety and tolerability of blinatumomab in adult patients with B-precursor Acute Lymphoblastic Leukemia who had relapsed following...

2012-06-01 10:22:07

NORTH WALES, Pa., June 1, 2012 /PRNewswire/ -- Teva Oncology presented two secondary analyses today featuring omacetaxine mepesuccinate, an investigational, first-in-class cephalotaxine that functions as a protein synthesis inhibitor at the American Society of Clinical Oncology Annual Meeting, June 1-5, 2012, Chicago. These analyses were derived from data that was submitted to the US Food and Drug Administration as part of a new drug application (NDA) and was recently accepted for review.(4)...